Monalizumab

Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]

Monalizumab
Monoclonal antibody
Type?
SourceHumanized
TargetNKG2A
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none

Mechanism of action

Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5]

References
  1. A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
  2. IPH2201 studies
  3. First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
  4. AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
  5. monalizumab


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.